Skip to main content
Top
Published in: Clinical Rheumatology 5/2018

01-05-2018 | Original Article

Serum uric acid levels are associated with lupus nephritis in patients with normal renal function

Authors: Ana Luisa Calich, Eduardo Ferreira Borba, Michelle Remião Ugolini-Lopes, Luiza Fuoco da Rocha, Eloisa Bonfá, Ricardo Fuller

Published in: Clinical Rheumatology | Issue 5/2018

Login to get access

Abstract

Uric acid has been recognised as a potential marker of endothelial dysfunction and kidney disease but there are scarce data about its importance in systemic lupus erythematosus (SLE) nephritis. This study aimed to evaluate serum uric acid (UA) levels in lupus nephritis (LN), by comparing SLE patients with normal renal function, with and without nephritis. Forty-six female SLE patients were consecutively selected and divided in two groups according to renal activity at the evaluation: presence of a recently diagnosed lupus nephritis (LN+, n = 18) and absence of lupus nephritis (LN−, n = 28). Age-matched healthy women were selected (CONTROL, n = 28). Patients with gout, creatinine clearance lower than 80 ml/min and use of drugs that interfere in UA were excluded. Laboratory and clinical data were analysed by appropriate tests. A multivariate analysis was performed, and a receiver operating characteristic (ROC) curve was plotted, and the area under the curve was calculated to assess the diagnostic strength of UA in LN. The mean age was similar among LN+, LN− and CONTROL groups (32.44 ± 6.09 vs. 30.68 ± 5.36 vs. 30.86 ± 5.00 years, p = 0.52). UA was significantly higher in LN+ compared to LN− (5.54 ± 1.67 vs. 3.65 ± 1.090 mg/dL, p < 0.001) and CONTROL (5.54 ± 1.67 vs. 3.92 ± 0.95 mg/dL p < 0.001). Multivariate analysis confirmed that high UA was an independent variable related to LN (p < 0.001). The cut-off value for UA using the ROC curve was 4.47 mg/dL (AUC 0.86, p = 0.00004, CI 95% 0.75–0.96). Lupus nephritis was associated with higher UA. Hyperuricemia as a predictor of renal damage in SLE needs to be evaluated in further studies.
Literature
6.
go back to reference Kang DH, Kanellis J (2005) Uric acid as a mediator of endothelial dysfunction, inflammation and vascular disease. Semin Nephrol 25:39–42CrossRefPubMed Kang DH, Kanellis J (2005) Uric acid as a mediator of endothelial dysfunction, inflammation and vascular disease. Semin Nephrol 25:39–42CrossRefPubMed
9.
go back to reference Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS (2010) High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 33(6):1337–1343. https://doi.org/10.2337/dc10-0227 CrossRefPubMedPubMedCentral Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS (2010) High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 33(6):1337–1343. https://​doi.​org/​10.​2337/​dc10-0227 CrossRefPubMedPubMedCentral
11.
go back to reference Reátegui-Sokolova C, Ugarte-Gil MF, Gamboa-Cárdenas RV, Zevallos F, Cucho-Venegas JM, Alfaro-Lozano JL, Medina M, Rodriguez-Bellido Z, Pastor-Asurza CA, Alarcón GS, Perich-Campos RA (2017) Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. Clin Rheumatol 36(4):845–852. https://doi.org/10.1007/s10067-017-3538-4 CrossRefPubMed Reátegui-Sokolova C, Ugarte-Gil MF, Gamboa-Cárdenas RV, Zevallos F, Cucho-Venegas JM, Alfaro-Lozano JL, Medina M, Rodriguez-Bellido Z, Pastor-Asurza CA, Alarcón GS, Perich-Campos RA (2017) Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. Clin Rheumatol 36(4):845–852. https://​doi.​org/​10.​1007/​s10067-017-3538-4 CrossRefPubMed
18.
go back to reference Myllymäki J, Honkanen T, Syrjänen J, Helin H, Rantala I, Pasternack A, Mustonen J (2005) Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 20:89–95CrossRefPubMed Myllymäki J, Honkanen T, Syrjänen J, Helin H, Rantala I, Pasternack A, Mustonen J (2005) Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 20:89–95CrossRefPubMed
23.
go back to reference Kang DH, Nakagawa T, Feng L, Watanabe S, Hen L, Mazzali M, Truong L, Harris R, Johnson RJ (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMed Kang DH, Nakagawa T, Feng L, Watanabe S, Hen L, Mazzali M, Truong L, Harris R, Johnson RJ (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMed
24.
go back to reference Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K, Sakima A, Iseki K, Ohya Y (2013) An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 36(1):43–49. https://doi.org/10.1038/hr.2012.135 Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K, Sakima A, Iseki K, Ohya Y (2013) An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 36(1):43–49. https://​doi.​org/​10.​1038/​hr.​2012.​135
25.
go back to reference Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241CrossRefPubMed Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241CrossRefPubMed
Metadata
Title
Serum uric acid levels are associated with lupus nephritis in patients with normal renal function
Authors
Ana Luisa Calich
Eduardo Ferreira Borba
Michelle Remião Ugolini-Lopes
Luiza Fuoco da Rocha
Eloisa Bonfá
Ricardo Fuller
Publication date
01-05-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-3991-8

Other articles of this Issue 5/2018

Clinical Rheumatology 5/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.